Most states allow some form of "medical marijuana". Medical marijuana is especially popular with pain patients, many of whom ...
The FDA has approved Journavx, a new non-opioid painkiller designed to treat moderate to severe acute pain. Unlike opioids, ...
The U.S. Food and Drug Administration has approved a novel prescription pain medication that targets sodium channels involved ...
A new painkiller that is said to be free of addiction risks may be transformative for treatment of acute pain, according to local medical professionals. "I think it could be a potentially ...
A new non-opioid painkiller, suzetrigine, has just been approved by the US drug regulator, the FDA. It is the first ...
The FDA has approved a new non-opioid prescription medication, Journavx for adults with moderate to severe acute pain.
The Phase IIa results continue a surge of momentum in a treatment space that last week saw the approval of Vertex’s Journavx ...
and Chronic Pain Center of Excellence for Canadian Veterans for research on pain management and perioperative care. Source Reference: Olejnik L, et al "Pharmacologic management of acute pain in ...
The FDA has approved suzetrigine, a groundbreaking non-opioid painkiller that targets pain at its source, offering a safer, ...
Journave, the first non-addictive opioid-like pain medication, was developed based on Yale research from the ’90s.
The Minnesota Department of Health has found that about 83,000 Minnesotans a year received chronic pain procedures during a three-year period. MDH was able to conduct this analysis for the ...
Experts discuss the current research on the use of digital therapeutics for managing chronic pain in rheumatic disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback